Compare Deere & Company (DE) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Halozyme Therapeutics Inc. Common Stock — how do they compare? Deere & Company trades at $620.93 (market cap $175.95B), while Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B). The key difference: Deere & Company is far larger — about 14× Halozyme Therapeutics Inc. Common Stock's market cap, and Deere & Company pays a 0.99% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| DE | HALO | |
|---|---|---|
Market Cap | $175.95B | $12.58B |
Volume | 1,387,231 | 2,179,278 |
Sector | Industrials | Health |
52-Week High | $709.48 | $115.22 |
52-Week Low | $439.11 | $61.63 |
Typical Hold Time | 75 Days | 1 Days |
Enterprise Value | $229.85B | $14.49B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 0.65% on the day, with technical indicators showing a bearish trend despite recent earnings beats. The stock faces cyclical headwinds as agricultural equipment demand softens, with revenue declining from $60.2B in 2023 to $44.7B in 2025. However, strong profitability metrics including 10.39% net margin and 18.4% ROE demonstrate operational resilience. Recent news highlights Deere's AI initiatives to boost farm efficiency and reverse sales trends.
While near-term agricultural cycle pressures persist, Deere's dominant market position and technological innovation provide long-term upside potential. The consensus price target of $731.20 suggests 12% upside, but investors should monitor equipment demand recovery and margin sustainability. Key risks include farm income volatility and elevated debt levels at 60.31% of assets.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
